obesity drug news today october 21 2025 glp-1 gains meet modest dip Drugmakers are racing to find

Description

Preclinical studies suggest that GLP-1 signaling in the mesolimbic reward circuits may reduce the reinforcing effects of substances such as nicotine, alcohol, and opioids

These drugs have different formulations and dosing schedules

Efficacy and safety of co-administered once-weekly cagrilintide 2 4 mg with once-weekly semaglutide 2 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

[DOI] [PubMed] [Google Scholar] 124.Bergmann N.C., Lund A., Gasbjerg L.S., Meessen E.C.E., Andersen M.M., Bergmann S., Hartmann B., Holst J.J., Jessen L., Christensen M.B., et al